Therapeutics and Clinical Risk Management (Jul 2015)

Adverse reaction to ceftriaxone in a 28-day-old infant undergoing urgent craniotomy due to epidural hematoma: review of neonatal biliary pseudolithiasis

  • Bartkowska-Śniatkowska A,
  • Jończyk-Potoczna K,
  • Zielińska M,
  • Rosada-Kurasińska J

Journal volume & issue
Vol. 2015, no. default
pp. 1035 – 1041

Abstract

Read online

Alicja Bartkowska-Śniatkowska,1 Katarzyna Jończyk-Potoczna,2 Marzena Zielińska,3 Jowita Rosada-Kurasińska1 1Department of Pediatric Anesthesiology and Intensive Therapy, Poznan University of Medical Sciences, Poznan, Poland; 2Department of Pediatric Radiology, Poznan University of Medical Sciences, Poznan, Poland; 3Department of Anesthesiology and Intensive Care, Pediatric Intensive Care Unit, Wroclaw Medical University, Wroclaw, Poland Abstract: The debate as to whether to administer ceftriaxone to neonates is likely to continue. Ceftriaxone has numerous advantages for critically ill pediatric patients. However, it is also known to contribute substantially to the development of biliary pseudolithiasis. Although pediatric patients rarely develop gallbladder disorders, this complication may lead to adverse events in high-risk patients with predisposing factors, particularly in neonates and infants treated with ceftriaxone. In this paper we present an interesting case report of a 28-day-old neonate with spontaneous severe epidural hematoma who developed biliary pseudolithiasis related to the use of ceftriaxone. We also discuss the efficacy of ceftriaxone in neonates and infants. Neonatologists and pediatric intensivists should be aware of the higher risk of co-existence of hyperbilirubinemia and gallbladder disorders while using ceftriaxone in pediatric settings. Keywords: ceftriaxone, pharmacodynamics, neonate, pseudolithiasis, efficacy